$OHCS
Optimus Healthcare Services, Inc. Stock $ohcs

$ohcs Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000121390024100736 Filed on November 21, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$384.8K	$453.7K
YoY Change		-15.2%	30.69%
Cost Of Revenue		$74.06K	$79.75K
YoY Change		-7.13%	22.65%
Gross Profit		$310.7K	$374.0K
YoY Change		-16.92%	32.55%
Gross Profit Margin		80.75%	82.42%
Selling, General & Admin			$1.720M
YoY Change			-35.13%
% of Gross Profit			459.93%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization		$3.409K	$7.774K
YoY Change		-56.15%	-498.67%
% of Gross Profit		1.1%	2.08%
Operating Expenses		$1.912M	$1.720M
YoY Change		11.15%	-35.12%
Operating Profit		-$1.601M	-$1.346M
YoY Change		18.95%	-43.18%
Interest Expense			$144.5K
YoY Change			38.55%
% of Operating Profit
Other Income/Expense, Net		-$205.1K	-$431.8K
YoY Change		-52.5%	-40.11%
Pretax Income		-$1.807M	-$1.778M
YoY Change		1.6%	-42.46%
Income Tax
% Of Pretax Income
Net Earnings		-$1.807M	-$1.778M
YoY Change		1.6%	-42.46%
Net Earnings / Revenue		-469.52%	-391.9%
Basic Earnings Per Share		-$0.04	-$0.04
Diluted Earnings Per Share		-$0.04	-$0.04
COMMON SHARES
Basic Shares Outstanding	50.02M shares	47.91M shares	39.97M shares
Diluted Shares Outstanding		47.88M shares	39.97M shares

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$340.0K
YoY Change		-68.45%
Cash & Equivalents	$152.4K	$200.4K
Short-Term Investments		$130.0K
Other Short-Term Assets
YoY Change
Inventory		$6.979K
Prepaid Expenses
Receivables		$570.0K
Other Receivables		$200.0K
Total Short-Term Assets	$418.1K	$1.114M
YoY Change	-62.46%	-33.72%
LONG-TERM ASSETS
Property, Plant & Equipment	$28.82K	$80.35K
YoY Change	-64.14%	165.01%
Goodwill		$815.5K
YoY Change		-77.57%
Intangibles		$2.000K
YoY Change		-99.88%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$211.4K	$1.236M
YoY Change	-82.89%	-78.42%
TOTAL ASSETS
Total Short-Term Assets	$418.1K	$1.114M
Total Long-Term Assets	$211.4K	$1.236M
Total Assets	$629.5K	$2.350M
YoY Change	-73.21%	-68.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.464M	$1.080M
YoY Change	35.51%	-31.95%
Accrued Expenses	$1.719M	$667.4K
YoY Change	157.59%	923.33%
Deferred Revenue
YoY Change
Short-Term Debt		$1.790M
YoY Change		1155.0%
Long-Term Debt Due		$3.630M
YoY Change		68390.57%
Total Short-Term Liabilities	$9.842M	$7.258M
YoY Change	35.6%	303.04%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$0.00	$2.839K
YoY Change	-100.0%	-99.06%
Total Long-Term Liabilities	$0.00	$2.839K
YoY Change	-100.0%	-99.9%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.842M	$7.258M
Total Long-Term Liabilities	$0.00	$2.839K
Total Liabilities	$9.973M	$7.513M
YoY Change	32.75%	64.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$33.81M	-$26.62M
YoY Change	27.01%	41.38%
Common Stock	$47.91K	$39.97K
YoY Change	19.86%	-0.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$9.340M	-$5.161M
YoY Change
Total Liabilities & Shareholders Equity	$629.5K	$2.350M
YoY Change	-73.21%	-68.27%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$1.807M	-$1.778M
YoY Change	1.6%	-42.46%
Depreciation, Depletion And Amortization	$3.409K	$7.774K
YoY Change	-56.15%	-498.67%
Cash From Operating Activities		-$880.0K
YoY Change		-0.01%
INVESTING ACTIVITIES
Capital Expenditures		$20.00K
YoY Change		-191.41%
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change
Cash From Investing Activities		-$10.00K
YoY Change		-54.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		900.0K
YoY Change		142.48%
NET CHANGE
Cash From Operating Activities		-880.0K
Cash From Investing Activities		-10.00K
Cash From Financing Activities		900.0K
Net Change In Cash		10.00K
YoY Change		-101.88%
FREE CASH FLOW
Cash From Operating Activities		-$880.0K
Capital Expenditures		$20.00K
Free Cash Flow		-$900.0K
YoY Change		4.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	ohcs	Paycheck Protection Program Loan Non Current PaycheckProtectionProgramLoanNonCurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2020Q2	us-gaap	Loans Receivable With Fixed Rates Of Interest1 LoansReceivableWithFixedRatesOfInterest1	145683	usd
CY2020Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	126546	usd
	us-gaap	Loans Receivable Description Of Variable Rate Basis LoansReceivableDescriptionOfVariableRateBasis	The unforgiven portion of the PPP loan totaling $19,137 is payable over five years at an interest rate of 1%, with a deferral of payments for the first twelve months.
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	usd
CY2024Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3554	usd
CY2024Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	4400000	usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	3915732	usd
CY2024Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	0	usd
CY2024Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	4400000	usd
CY2022Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2200000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	599773	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	363083	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	205169	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	144499	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	484268	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	864454	usd
CY2024Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
CY2023Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	291318	usd
CY2024Q1	ohcs	Gross Proceeds GrossProceeds	2000000	usd
CY2024Q1	us-gaap	Convertible Subordinated Debt ConvertibleSubordinatedDebt	350000	usd
	ohcs	Other Transaction Document Between The Parties For Liquidate Damages OtherTransactionDocumentBetweenThePartiesForLiquidateDamages	197817	usd
	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	3165066	shares
	ohcs	Percentage Of Outstanding Principal Rate PercentageOfOutstandingPrincipalRate	0.12	pure
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	333-261849
	dei	Entity Registrant Name EntityRegistrantName	OPTIMUS HEALTHCARE SERVICES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	FL
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	65-0181535
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1400 Old Country Road
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 306
	dei	Entity Address City Or Town EntityAddressCityOrTown	Westbury
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	11590
	dei	City Area Code CityAreaCode	(516)
	dei	Local Phone Number LocalPhoneNumber	806-4201
	dei	Security12b Title Security12bTitle	None
	dei	No Trading Symbol Flag NoTradingSymbolFlag	true
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	50018664	shares
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	152357	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100319	usd
CY2024Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	248258	usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	572707	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	100000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	17485	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	33592	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	418100	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	806618	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	182604	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	224316	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28816	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	39164	usd
CY2024Q3	us-gaap	Assets Assets	629520	usd
CY2023Q4	us-gaap	Assets Assets	1070098	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1464151	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1154309	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1719204	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1043270	usd
CY2024Q3	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	132896	usd
CY2023Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	135744	usd
CY2024Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	4400000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3915732	usd
CY2024Q3	ohcs	Paycheck Protection Program Loan Current PaycheckProtectionProgramLoanCurrent	3554	usd
CY2023Q4	ohcs	Paycheck Protection Program Loan Current PaycheckProtectionProgramLoanCurrent	5304	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	62524	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	59765	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	9842329	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8034124	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	130934	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	175344	usd
CY2023Q4	ohcs	Paycheck Protection Program Loan Non Current PaycheckProtectionProgramLoanNonCurrent	1592	usd
CY2024Q3	us-gaap	Liabilities Liabilities	9973263	usd
CY2023Q4	us-gaap	Liabilities Liabilities	8211060	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47906664	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47906664	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39967598	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39967598	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	47907	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	39968	usd
CY2023Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	550	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	24418625	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	22947709	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33814142	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-30133916	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-9339502	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-7137581	usd
CY2024Q3	us-gaap	Minority Interest MinorityInterest	-4241	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-3381	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-9343743	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-7140962	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	629520	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1070098	usd
CY2024Q3	us-gaap	Revenues Revenues	384763	usd
CY2023Q3	us-gaap	Revenues Revenues	453717	usd
	us-gaap	Revenues Revenues	1368531	usd
	us-gaap	Revenues Revenues	1047773	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	74061	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	79750	usd
	us-gaap	Cost Of Revenue CostOfRevenue	194304	usd
	us-gaap	Cost Of Revenue CostOfRevenue	218932	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	310702	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	373967	usd
	us-gaap	Gross Profit GrossProfit	1174227	usd
	us-gaap	Gross Profit GrossProfit	828841	usd
CY2024Q3	us-gaap	Share Based Compensation ShareBasedCompensation	986347	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	682452	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	752632	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3283913	usd
CY2024Q3	us-gaap	Other General Expense OtherGeneralExpense	424856	usd
CY2023Q3	us-gaap	Other General Expense OtherGeneralExpense	448836	usd
	us-gaap	Other General Expense OtherGeneralExpense	1333890	usd
	us-gaap	Other General Expense OtherGeneralExpense	2179288	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	447926	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	472544	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1235033	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1499633	usd
CY2024Q3	us-gaap	Professional Fees ProfessionalFees	53003	usd
CY2023Q3	us-gaap	Professional Fees ProfessionalFees	116437	usd
	us-gaap	Professional Fees ProfessionalFees	191027	usd
	us-gaap	Professional Fees ProfessionalFees	319916	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	1912132	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	1720269	usd
	us-gaap	Operating Expenses OperatingExpenses	3512582	usd
	us-gaap	Operating Expenses OperatingExpenses	7282750	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1601430	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1346302	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2338355	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6453909	usd
CY2023Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	291318	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	484268	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	864454	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	205169	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	144499	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	599773	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	363083	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-263857	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	78510	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	67	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	4000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	6143	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	12000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-205102	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-431817	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1341755	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1137027	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1806532	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1778119	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3680110	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7590936	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	976	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2025	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-1806532	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1778119	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3681086	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7592961	usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	388	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	593	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	860	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1486	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-1806144	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-1777526	usd
	us-gaap	Profit Loss ProfitLoss	-3680226	usd
	us-gaap	Profit Loss ProfitLoss	-7591475	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-1806532	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1778119	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3681086	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7592961	usd
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47883707	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47883707	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39967598	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39967598	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44809922	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44809922	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39967517	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39967517	shares
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-7140962	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-15282	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	-1116786	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	411459	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	50215	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-423487	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8234843	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	898352	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	132000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1451067	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8655558	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	986347	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	132000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-1806532	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-9343743	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1642522	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	725000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	206755	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1211188	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2954465	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2454044	usd
CY2023Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	136827	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	188795	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	994723	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2860377	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4267730	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	200000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-384690	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1067142	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1778119	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-5163397	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3681086	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7592961	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10349	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12026	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	752632	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3283913	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	78510	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-263857	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	484268	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	864454	usd
	ohcs	Amortization Of Rightofuse Asset AmortizationOfRightofuseAsset	59	usd
	ohcs	Amortization Of Rightofuse Asset AmortizationOfRightofuseAsset	-2591	usd
	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	-424449	usd
	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	46046	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6979	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-16107	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	29853	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	309842	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	342078	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1137751	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	85611	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-281772	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3168858	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	936330	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	713622	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	35431	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	187277	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	925000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	136827	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	340000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1649800	usd
	ohcs	Payment Of Paycheck Protection Program Loan PaymentOfPaycheckProtectionProgramLoan	3342	usd
	ohcs	Payment Of Paycheck Protection Program Loan PaymentOfPaycheckProtectionProgramLoan	3723	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	2848	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	3318	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	333810	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2430932	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	52038	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-550649	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100319	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	751017	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	152357	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	200368	usd
	us-gaap	Interest Paid Net InterestPaidNet	200700	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	976	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	2025	usd
	us-gaap	Stock Issued1 StockIssued1	675459	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>1. Nature of operations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Optimus Healthcare Services, Inc. (formerly Between Dandelions, Inc., “Optimus”, “Company”) was initially organized under the laws of Florida on February 26, 1990, as Phoenix Management Associates, Inc. Over the ensuing years, the Company made a series of amendments to its Articles of Incorporation relating to authorization of various series of Preferred Shares and made a series of name changes. The current name of Optimus Healthcare Services, Inc. became effective with the State of Florida on January 24, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company is dedicated to advancing access to clinical trial research through its portfolio company Clinical Research Alliance, Inc. (“CRA”), and until December 2023 when it discontinued operations of its early stage pharmacy operation, through its portfolio company Worker’s Health Rx (d/b/a “Vitality Rx”).</span></p>
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	1990-02-26
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Use of Estimates</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant assumptions and estimates relate to the valuation of equity issued for services, valuation of equity associated with convertible debt, the valuation of derivative liabilities, and the valuation of deferred tax assets. Actual results could differ from these estimates.</span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; background-color: white"><span style="text-decoration:underline">Concentration of Credit Risk</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable. The Company places its cash equivalents with financial institutions and invests its excess cash primarily in certificates of deposit, deposit accounts or treasury bills. The Company has established guidelines relative to credit ratings and maturities that seek to maintain stability and liquidity.</span></p>
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	152357	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	100319	usd
CY2024Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	0	usd
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	0	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	815500	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3310120	usd
	ohcs	Expense Recovery Amount ExpenseRecoveryAmount	2557488	usd
	ohcs	Expense Recovery Amount ExpenseRecoveryAmount	2557488	usd
	ohcs	Expense Recovery Amount ExpenseRecoveryAmount	1250508	usd
	ohcs	Expense Recovery Amount ExpenseRecoveryAmount	1250508	usd
CY2023Q3	ohcs	Expense Recovery Amount ExpenseRecoveryAmount	682452	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1932960	usd
	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.50	pure
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	79772914	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7586664	shares
	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The Company entered into a lease agreement commencing on July 1, 2023 through September 30, 2026 for 2,153 square feet of office space located at One Dupont Street, Suite 112, Plainview, New York, 11803.
CY2024Q2	us-gaap	Settlement Assets Current SettlementAssetsCurrent	6100	usd
CY2024Q2	us-gaap	Security Deposit SecurityDeposit	5250	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	158	usd
	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.075	pure
	us-gaap	Payments For Rent PaymentsForRent	71632	usd
	us-gaap	Payments For Rent PaymentsForRent	90618	usd
CY2024Q3	us-gaap	Payments For Rent PaymentsForRent	23721	usd
CY2023Q3	us-gaap	Payments For Rent PaymentsForRent	28892	usd
CY2024Q3	ohcs	Operating Lease Right Of Use Asset Office Lease OperatingLeaseRightOfUseAssetOfficeLease	371832	usd
CY2023Q4	ohcs	Operating Lease Right Of Use Asset Office Lease OperatingLeaseRightOfUseAssetOfficeLease	371832	usd
CY2024Q3	ohcs	Operating Lease Right Of Use Asset Equipment Lease OperatingLeaseRightOfUseAssetEquipmentLease	3773	usd
CY2023Q4	ohcs	Operating Lease Right Of Use Asset Equipment Lease OperatingLeaseRightOfUseAssetEquipmentLease	5676	usd
CY2024Q3	ohcs	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	193001	usd
CY2023Q4	ohcs	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	153192	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	182604	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	224316	usd
CY2024Q3	ohcs	Operating Lease Liability Office Lease OperatingLeaseLiabilityOfficeLease	189157	usd
CY2023Q4	ohcs	Operating Lease Liability Office Lease OperatingLeaseLiabilityOfficeLease	229433	usd
CY2024Q3	ohcs	Operating Lease Liability Equipment Lease OperatingLeaseLiabilityEquipmentLease	4301	usd
CY2023Q4	ohcs	Operating Lease Liability Equipment Lease OperatingLeaseLiabilityEquipmentLease	5676	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	62524	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	59765	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	130934	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	175344	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	21580	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	71323	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	73223	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	49677	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	215803	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	22345	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	193458	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	152357	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	100319	usd
CY2024Q3	ohcs	Working Capital Deficit WorkingCapitalDeficit	9424229	usd
CY2023Q4	ohcs	Working Capital Deficit WorkingCapitalDeficit	7227506	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3681086	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7592961	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-1806532	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1778119	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33814142	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-30133916	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	815500	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-37979	usd
CY2022Q4	us-gaap	Loans Payable LoansPayable	200000	usd
CY2022Q4	us-gaap	Other Additional Capital OtherAdditionalCapital	100000	usd
CY2022Q4	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	3600000	usd
CY2022Q4	us-gaap	Beneficial Interest BeneficialInterest	100000	usd
CY2022Q4	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	3500000	usd
CY2022Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	3627927	usd
CY2022Q4	us-gaap	Gain Loss On Sale Of Property GainLossOnSaleOfProperty	127927	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	100000	usd
	us-gaap	Liabilities Average Amount Outstanding LiabilitiesAverageAmountOutstanding	100000	usd
CY2024Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	19880	usd
CY2023Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	19880	usd
CY2024Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	43784	usd
CY2023Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	43784	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	63664	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	63664	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	34848	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	24500	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28816	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	39164	usd
CY2024Q3	us-gaap	Depreciation Depreciation	3409	usd
	us-gaap	Depreciation Depreciation	10349	usd
CY2023Q3	us-gaap	Depreciation Depreciation	7774	usd
	us-gaap	Depreciation Depreciation	11276	usd
CY2024Q3	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	132896	usd
CY2023Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	135744	usd
	ohcs	Agreements Liquidated Damages AgreementsLiquidatedDamages	20000	usd
	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	4861674	usd
	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	4597817	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-263857	usd
CY2021Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2000000	shares
CY2023	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	1275000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	usd
CY2024Q3	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	1100000001	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1000000000	shares
CY2024Q3	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	1100000001	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1000000000	shares
	us-gaap	Common Stock Convertible Conversion Price Increase CommonStockConvertibleConversionPriceIncrease	1.25
	ohcs	Preferred Stock Voting Rightsshare PreferredStockVotingRightsshare	1.25
CY2020Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	9998899	shares
CY2020Q4	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	9998889	shares
CY2024Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.075
	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	0.0999	pure
CY2024Q3	us-gaap	Share Price SharePrice	0.25
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.25
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.6797	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0389	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M12D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9882500	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.43
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y10M28D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5155000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.25
	ohcs	Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Remaining Term Options Granted SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingTermOptionsGranted	P10Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	3062500	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.64
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11975000	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.87
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y11M26D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	7261250	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.77
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P9Y3M
	ohcs	Share Based Compensation Reversal For Stock Cancellation ShareBasedCompensationReversalForStockCancellation	2542206	usd
	ohcs	Share Based Compensation Reversal For Stock Cancellation ShareBasedCompensationReversalForStockCancellation	861398	usd
CY2023Q3	ohcs	Share Based Compensation Reversal For Stock Cancellation ShareBasedCompensationReversalForStockCancellation	861398	usd
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2435707	usd
	ohcs	Percentage Of Restricted Stock Vest PercentageOfRestrictedStockVest	0.25	pure
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	399971	usd
	us-gaap	Recovery Of Direct Costs RecoveryOfDirectCosts	389111	usd
CY2024Q3	us-gaap	Restricted Stock Expense RestrictedStockExpense	0	usd
CY2023Q3	us-gaap	Restricted Stock Expense RestrictedStockExpense	384690	usd
CY2023Q3	us-gaap	Restricted Stock Expense RestrictedStockExpense	384690	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	4421	usd
CY2023Q3	us-gaap	Recovery Of Direct Costs RecoveryOfDirectCosts	389111	usd
CY2024Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent		usd
CY2024Q3	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions		usd
CY2024Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts		usd
CY2024Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2024Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments		usd
CY2023Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments		usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments		usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices		usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Stock Issued1 StockIssued1		usd
CY2024Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent		usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001892025

Files In Submission

Name	View Source	Status
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
0001213900-24-100736-index-headers.html	Edgar Link	pending
0001213900-24-100736-index.html	Edgar Link	pending
0001213900-24-100736.txt	Edgar Link	pending
0001213900-24-100736-xbrl.zip	Edgar Link	pending
ea0221741-10q_optimus.htm	Edgar Link	pending
ea022174101ex10-3_optimus.htm	Edgar Link	pending
ea022174101ex31-1_optimus.htm	Edgar Link	pending
ea022174101ex31-2_optimus.htm	Edgar Link	pending
ea022174101ex32-1_optimus.htm	Edgar Link	pending
ea0221741-10q_optimus_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
ea022174101ex32-2_optimus.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ohcs-20240930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
ohcs-20240930_def.xml	Edgar Link	unprocessable
ohcs-20240930_cal.xml	Edgar Link	unprocessable
ohcs-20240930_lab.xml	Edgar Link	unprocessable
ohcs-20240930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OHCS
Optimus Healthcare Services, Inc. Stock $ohcs

2024 Q4 Form 10-Q Financial Statement

#000121390024100736 Filed on November 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OHCS Optimus Healthcare Services, Inc. Stock $ohcs

2024 Q4 Form 10-Q Financial Statement

#000121390024100736 Filed on November 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OHCS
Optimus Healthcare Services, Inc. Stock $ohcs